Xinyu He

Xinyu He

Auto-generated profile, based on publicly available information

Xinyu He

State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2023 in Oncogene
Verified
Journal Article
Closed access
PDF file
XHXinyu He
Xinyu He
YZYubing Zhou
Yubing Zhou
WCWenjing Chen
Wenjing Chen
XZXiaokun Zhao
Xiaokun Zhao
LDLina Duan
Lina Duan
KLKangdong Liu
Kangdong Liu

15 February 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Xiang WangXiang Wang
Xiang Wang
ZYZijun Yuan
Zijun Yuan
ZLZhengbo Li
Zhengbo Li
XHXinyu He
Xinyu He
YZYinping Zhang
Yinping Zhang
ZXZhangang Xiao
Zhangang Xiao
The incidence of hepatocellular carcinoma (HCC) ranks first among primary liver cancers, and its mortality rate exhibits a consistent annual increase. The treatment of HCC has witnessed a significant surge in recent years, with the emergence of targeted immune therapy as an adjunct to early surgical resection. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has shown promising results in other types of solid tumors. This article aims to provide a comprehensive overview of the intricate interactions between different types of TILs and their impact on HCC, elucidate strategies for targeting neoantigens through TILs, and address the challenges encountered in TIL therapies along with potential solutions. Furthermore, this article specifically examines the impact of oncogenic signaling pathways activation within the HCC tumor microenvironment on the infiltration dynamics of TILs. Additionally, a concise overview is provided regarding TIL preparation techniques and an update on clinical trials investigating TIL-based immunotherapy in solid tumors.

27 April 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YZYafei Zhi
Yafei Zhi
YGYan Guo
Yan Guo
SLShiliang Li
Shiliang Li
XHXinyu He
Xinyu He
HWHuifang Wei
Huifang Wei
KLKangdong Liu
Kangdong Liu
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Accumulating evidence suggests that epigenetic dysregulation contributes to the initiation and progression of HCC. We aimed to investigate key epigenetic regulators that contribute to tumorigenesis and progression, providing a theoretical basis for targeted therapy for HCC. We performed a comprehensive epigenetic analysis of differentially expressed genes in LIHC from the TCGA database. We identified fibrillarin (FBL), an rRNA 2′-O-methyltransferase, as an essential contributor to HCC. A series of in vitro and in vivo biological experiments were performed to investigate the potential mechanisms of FBL. FBL knockdown suppressed the proliferation of HCC cells. In vivo studies using cell-derived xenograft (CDX), patient-derived xenograft (PDX), and diethylnitrosamine (DEN)-induced HCC models in Fbl liver-specific knockout mice demonstrated the critical role of FBL in HCC carcinogenesis and progression. Mechanistically, FBL regulates the expression of CAD in HCC cells by recruiting YY1 to the CAD promoter region. We also revealed that fludarabine phosphate is a novel inhibitor of FBL and can inhibit HCC growth in vitro and in vivo. The antitumor activity of lenvatinib has been shown to be synergistically enhanced by fludarabine phosphate. Our study highlights the cancer-promoting role of the FBL-YY1-CAD axis in HCC and identifies fludarabine phosphate as a novel inhibitor of FBL.

25 June 2026 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
XHXinyu He
Xinyu He
DZDengyun Zhao
Dengyun Zhao
YZYubing Zhou
Yubing Zhou
YJYanan Jiang
Yanan Jiang
ZDZigang Dong
Zigang Dong
KLKangdong Liu
Kangdong Liu